Downloads: 165

Files in This Item:
File Description SizeFormat 
cas.13265.pdf441.06 kBAdobe PDFView/Open
Title: Clinical sequencing using a next-generation sequencing-based multiplex gene assay in patients with advanced solid tumors
Authors: Kou, Tadayuki
Kanai, Masashi  kyouindb  KAKEN_id
Yamamoto, Yoshihiro
Kamada, Mayumi
Nakatsui, Masahiko
Sakuma, Tomohiro
Mochizuki, Hiroaki
Hiroshima, Akinori
Sugiyama, Aiko
Nakamura, Eijiro
Miyake, Hidehiko
Minamiguchi, Sachiko  kyouindb  KAKEN_id
Takaori, Kyoichi  kyouindb  KAKEN_id
Matsumoto, Shigemi  kyouindb  KAKEN_id
Haga, Hironori  kyouindb  KAKEN_id
Seno, Hiroshi  kyouindb  KAKEN_id
Kosugi, Shinji  kyouindb  KAKEN_id  orcid (unconfirmed)
Okuno, Yasushi  kyouindb  KAKEN_id
Muto, Manabu  kyouindb  KAKEN_id
Author's alias: 髙 忠之
金井, 雅史
山本, 佳宏
鎌田, 真由美
中津井, 雅彦
杉山, 愛子
中村, 英二郎
三宅, 秀彦
南口, 早智子
高折, 恭一
松本, 繁巳
羽賀, 博典
妹尾, 浩
小杉, 眞司
奥野, 恭史
武藤, 学
Keywords: Actionable mutation
genotype-directed therapy
multiplex gene assay
next-generation sequencing
precision cancer medicine
Issue Date: Jul-2017
Publisher: Wiley-Blackwell
Journal title: Cancer Science
Volume: 108
Issue: 7
Start page: 1440
End page: 1446
Abstract: Advances in next-generation sequencing (NGS) technologies have enabled physicians to test for genomic alterations in multiple cancer-related genes at once in daily clinical practice. In April 2015, we introduced clinical sequencing using an NGS-based multiplex gene assay (OncoPrime) certified by the Clinical Laboratory Improvement Amendment. This assay covers the entire coding regions of 215 genes and the rearrangement of 17 frequently rearranged genes with clinical relevance in human cancers. The principal indications for the assay were cancers of unknown primary site, rare tumors, and any solid tumors that were refractory to standard chemotherapy. A total of 85 patients underwent testing with multiplex gene assay between April 2015 and July 2016. The most common solid tumor types tested were pancreatic (n = 19; 22.4%), followed by biliary tract (n = 14; 16.5%), and tumors of unknown primary site (n = 13; 15.3%). Samples from 80 patients (94.1%) were successfully sequenced. The median turnaround time was 40 days (range, 18–70 days). Potentially actionable mutations were identified in 69 of 80 patients (86.3%) and were most commonly found in TP53 (46.3%), KRAS (23.8%), APC (18.8%), STK11 (7.5%), and ATR (7.5%). Nine patients (13.0%) received a subsequent therapy based on the NGS assay results. Implementation of clinical sequencing using an NGS-based multiplex gene assay was feasible in the clinical setting and identified potentially actionable mutations in more than 80% of patients. Current challenges are to incorporate this genomic information into better therapeutic decision making.
Rights: © 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
DOI(Published Version): 10.1111/cas.13265
PubMed ID: 28440963
Appears in Collections:Journal Articles

Show full item record

Export to RefWorks

Export Format: 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.